Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

mAbs

Volumn 1, Issue 1, 2009, Pages 41-48

  Ramakrishnan, Melarkode S ^a   Eswaraiah, Anand ^b   Crombet, Tania ^c   Piedra, Patricia ^c   Saurez, Giselle ^c   Iyer, Harish ^a   Arvind, A S ^b  

^a Biocon Limited   (India)

^b Clinigene International Limited   (India)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

EGFR; Glioma; Humanized; Monoclonal antibody; Nimotuzumab; Overall survival; SCCHN

Indexed keywords

CETUXIMAB; CISPLATIN; MATUZUMAB; NIMOTUZUMAB; PANITUMUMAB;

ACNE; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BINDING AFFINITY; BLOOD PRESSURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG INFUSION REACTION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPITHELIUM TUMOR; GASTROINTESTINAL TOXICITY; GLIOMA; HEAD AND NECK CARCINOMA; HEMATURIA; HUMAN; HYPERTENSION; LOOSE FECES; MICROSCOPIC HEMATURIA; NASOPHARYNX CANCER; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; URTICARIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CUBA; GLIOMA; HEAD AND NECK NEOPLASMS; HUMANS; INDIA; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77953664765     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.1.7509     Document Type: Review

References (19)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl J Med 2008; 358:1160-1174
2. Speake G, Holloway B, Costello G. Recent developments related to the EGFR as a target for cancer chemotherapy. Curr Opin Pharmacol 2005; 5:343-349 (Pubitemid 40932035)
3. Hynes NE, Lane HA. Errb receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-354 (Pubitemid 40637826)
4. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30:255-268 (Pubitemid 38477271)
5. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71-78 (Pubitemid 27197395)
6. Fernandez A, Spitzer E, Perez R, Boehmer FD, Eckert K, Zschiesche W, et al. A new monoclonal antibody for the detection of EGF-R in Western blot and paraffin embedded tissue sections. J Cell Biochem 1992; 49:157-165
7. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-r3: a humanized anti-egfr antibody. Int J Cancer 2002; 101:567-575
8. Miqueli AD, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, et al. Biological activity in vitro of anti-Epidermal Growth Factor Receptor monoclonal antibodies with different affinities. Hybridoma 2007; 26:423-431
9. Arteaga ME, Ledón N, Casacó A, Pardo B, García M, Boleda M, et al. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 Weeks with a high intravenous dose of the anti-Epidermal Growth Factor Receptor monoclonal antibody nimotuzumab. Cancer Biol Ther 2007; 6:1390-1395
10. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/ 089404en6.pdf. Accessed 2007.
11. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-Epidermal Growth Factor Receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646-1654 (Pubitemid 41079803)
12. Allan D. Nimotuzumab: Evidence of clinical benefit without rash. Oncologist 2005; 10:760-761 (Pubitemid 41567290)
13. Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, et al. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: Effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 1992; 52:357-366
14. Tikhomirov IA, Hidalgo GG, Yang E, Sherman I, Rodriguez RP. Bivalent binding properties of Epidermal Growth Factor Receptor (EGFR) targeted monoclonal antibodies: factors contributing to differences in observed clinical profiles 2008; AACR Meeting on Cancer Clinical Trials and Personalized Medicine.
15. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657-670 (Pubitemid 44436627)
16. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anti-Cancer Drug 2007; 18:7-15. (Pubitemid 44949790)
17. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, et al. J Phase I study of the humanized anti-epidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:175-184 (Pubitemid 41095130)
18. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6:175-182 (Pubitemid 46380811)
19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 2006; 354:567-578 (Pubitemid 43209104)